US 12,570,727 B2Granted

Antibodies specifically recognizing Pseudomonas Psl and uses thereof

AssigneeBeijing Solobio Genetechnology Company Ltd.

InventorsZhong Li, Maorong Yu

Life of this patent

Estimating the term…

Abstract

Provided herein are antibodies including antigen-binding fragments thereof that specifically recognizing Pseudomonas Psl. Also provided are methods of making and using these antibodies.

Claims9

Dependent claims

An isolated antibody or antigen binding fragment thereof which specially binds to Pseudomonas Psl, comprises:

a VH comprising an HC-CDR1 comprising the amino acid sequence of SEQ ID NO:
1, an HC-CDR2 comprising the amino acid sequence of SEQ ID NO:
13, and an HC-CDR3 comprising the amino acid sequence of SEQ ID NO:
24;
and a VL comprising an LC-CDR1 comprising the amino acid sequence of SEQ ID NO:
37, an LC-CDR2 comprising the amino acid sequence of SEQ ID NO:
51, and an LC-CDR3 comprising the amino acid sequence of SEQ ID NO:
62;
(ii) a VH comprising an HC-CDR1 comprising the amino acid sequence of SEQ ID NO:
1, an HC-CDR2 comprising the amino acid sequence of SEQ ID NO:
163, and an HC-CDR3 comprising the amino acid sequence of SEQ ID NO:
171;
and a VL comprising an LC-CDR1 comprising the amino acid sequence of SEQ ID NO:
37, an LC-CDR2 comprising the amino acid sequence of SEQ ID NO:
51, and an LC-CDR3 comprising the amino acid sequence of SEQ ID NO:
62;
(iii) a VH comprising an HC-CDR1 comprising the amino acid sequence of SEQ ID NO:
1, an HC-CDR2 comprising the amino acid sequence of SEQ ID NO:
163, and an HC-CDR3 comprising the amino acid sequence of SEQ ID NO:
172;
and a VL comprising an LC-CDR1 comprising the amino acid sequence of SEQ ID NO:
37, an LC-CDR2 comprising the amino acid sequence of SEQ ID NO:
51, and an LC-CDR3 comprising the amino acid sequence of SEQ ID NO:
62;
(iv) a VH comprising an HC-CDR1 comprising the amino acid sequence of SEQ ID NO:
1, an HC-CDR2 comprising the amino acid sequence of SEQ ID NO:
163, and an HC-CDR3 comprising the amino acid sequence of SEQ ID NO:
173;
and a VL comprising an LC-CDR1 comprising the amino acid sequence of SEQ ID NO:
37, an LC-CDR2 comprising the amino acid sequence of SEQ ID NO:
51, and an LC-CDR3 comprising the amino acid sequence of SEQ ID NO:
62;
(v) a VH comprising an HC-CDR1 comprising the amino acid sequence of SEQ ID NO:
1, an HC-CDR2 comprising the amino acid sequence of SEQ ID NO:
163, and an HC-CDR3 comprising the amino acid sequence of SEQ ID NO:
36;
and a VL comprising an LC-CDR1 comprising the amino acid sequence of SEQ ID NO:
37, an LC-CDR2 comprising the amino acid sequence of SEQ ID NO:
51, and an LC-CDR3 comprising the amino acid sequence of SEQ ID NO:
62;
(vi) a VH comprising an HC-CDR1 comprising the amino acid sequence of SEQ ID NO:
1, an HC-CDR2 comprising the amino acid sequence of SEQ ID NO:
163, and an HC-CDR3 comprising the amino acid sequence of SEQ ID NO:
174;
and a VL comprising an LC-CDR1 comprising the amino acid sequence of SEQ ID NO:
37, an LC-CDR2 comprising the amino acid sequence of SEQ ID NO:
51, and an LC-CDR3 comprising the amino acid sequence of SEQ ID NO:
62;
(vii) a VH comprising an HC-CDR1 comprising the amino acid sequence of SEQ ID NO:
1, an HC-CDR2 comprising the amino acid sequence of SEQ ID NO:
163, and an HC-CDR3 comprising the amino acid sequence of SEQ ID NO:
175;
and a VL comprising an LC-CDR1 comprising the amino acid sequence of SEQ ID NO:
37, an LC-CDR2 comprising the amino acid sequence of SEQ ID NO:
51, and an LC-CDR3 comprising the amino acid sequence of SEQ ID NO:
62;
(viii) a VH comprising an HC-CDR1 comprising the amino acid sequence of SEQ ID NO:
1, an HC-CDR2 comprising the amino acid sequence of SEQ ID NO:
163, and an HC-CDR3 comprising the amino acid sequence of SEQ ID NO:
176;
and a VL comprising an LC-CDR1 comprising the amino acid sequence of SEQ ID NO:
37, an LC-CDR2 comprising the amino acid sequence of SEQ ID NO:
51, and an LC-CDR3 comprising the amino acid sequence of SEQ ID NO:
62;
(ix) a VH comprising an HC-CDR1 comprising the amino acid sequence of SEQ ID NO:
1, an HC-CDR2 comprising the amino acid sequence of SEQ ID NO:
163, and an HC-CDR3 comprising the amino acid sequence of SEQ ID NO:
177;
and a VL comprising an LC-CDR1 comprising the amino acid sequence of SEQ ID NO:
37, an LC-CDR2 comprising the amino acid sequence of SEQ ID NO:
51, and an LC-CDR3 comprising the amino acid sequence of SEQ ID NO:
62;
(x) a VH comprising an HC-CDR1 comprising the amino acid sequence of SEQ ID NO:
1, an HC-CDR2 comprising the amino acid sequence of SEQ ID NO:
163, and an HC-CDR3 comprising the amino acid sequence of SEQ ID NO:
178;
and a VL comprising an LC-CDR1 comprising the amino acid sequence of SEQ ID NO:
37, an LC-CDR2 comprising the amino acid sequence of SEQ ID NO:
51, and an LC-CDR3 comprising the amino acid sequence of SEQ ID NO:
62;
(xi) a VH comprising an HC-CDR1 comprising the amino acid sequence of SEQ ID NO:
1, an HC-CDR2 comprising the amino acid sequence of SEQ ID NO:
163, and an HC-CDR3 comprising the amino acid sequence of SEQ ID NO:
179;
and a VL comprising an LC-CDR1 comprising the amino acid sequence of SEQ ID NO:
37, an LC-CDR2 comprising the amino acid sequence of SEQ ID NO:
51, and an LC-CDR3 comprising the amino acid sequence of SEQ ID NO:
62;
(xii) a VH comprising an HC-CDR1 comprising the amino acid sequence of SEQ ID NO:
1, an HC-CDR2 comprising the amino acid sequence of SEQ ID NO:
163, and an HC-CDR3 comprising the amino acid sequence of SEQ ID NO:
180;
and a VL comprising an LC-CDR1 comprising the amino acid sequence of SEQ ID NO:
37, an LC-CDR2 comprising the amino acid sequence of SEQ ID NO:
51, and an LC-CDR3 comprising the amino acid sequence of SEQ ID NO:
62;
(xiii) a VH comprising an HC-CDR1 comprising the amino acid sequence of SEQ ID NO:
1, an HC-CDR2 comprising the amino acid sequence of SEQ ID NO:
13, and an HC-CDR3 comprising the amino acid sequence of SEQ ID NO:
181;
and a VL comprising an LC-CDR1 comprising the amino acid sequence of SEQ ID NO:
37, an LC-CDR2 comprising the amino acid sequence of SEQ ID NO:
51, and an LC-CDR3 comprising the amino acid sequence of SEQ ID NO:
62;
(xiv) a VH comprising an HC-CDR1 comprising the amino acid sequence of SEQ ID NO:
1, an HC-CDR2 comprising the amino acid sequence of SEQ ID NO:
163, and an HC-CDR3 comprising the amino acid sequence of SEQ ID NO:
182;
and a VL comprising an LC-CDR1 comprising the amino acid sequence of SEQ ID NO:
37, an LC-CDR2 comprising the amino acid sequence of SEQ ID NO:
51, and an LC-CDR3 comprising the amino acid sequence of SEQ ID NO:
62;
(xv) a VH comprising an HC-CDR1 comprising the amino acid sequence of SEQ ID NO:
1, an HC-CDR2 comprising the amino acid sequence of SEQ ID NO:
163, and an HC-CDR3 comprising the amino acid sequence of SEQ ID NO:
185;
and a VL comprising an LC-CDR1 comprising the amino acid sequence of SEQ ID NO:
37, an LC-CDR2 comprising the amino acid sequence of SEQ ID NO:
51, and an LC-CDR3 comprising the amino acid sequence of SEQ ID NO:
62;
or
(xvi) a VH comprising an HC-CDR1 comprising the amino acid sequence of SEQ ID NO:
1, an HC-CDR2 comprising the amino acid sequence of SEQ ID NO:
163, and an HC-CDR3 comprising the amino acid sequence of SEQ ID NO:
186;
and a VL comprising an LC-CDR1 comprising the amino acid sequence of SEQ ID NO:
37, an LC-CDR2 comprising the amino acid sequence of SEQ ID NO:
51, and an LC-CDR3 comprising the amino acid sequence of SEQ ID NO:
62.

126 more elements

Dependencies are inferred from the claim text.

Facts

Application: 18/020,180Filed 4 Aug 2021
Priority: WO PCT/CN2020/1076667 Aug 2020
Published: US 2023/0295279 A121 Sep 2023
Granted: 10 Mar 2026
Term ends: Not estimatedThe source records don’t support an estimate.

Classification21 codes

C07K 16/1214
Gram-negative bacteria: pseudomonadaceae
A61K 39/395
Medicinal preparations containing antigens or antibodies: antibodies ; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
A61P 31/04
Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics: antibacterial agents
C12N 15/85
Vectors or expression systems specially adapted for eukaryotic hosts: for animal cells

Family

US 2023/0295279 A1Pre-grant publication · published 21 Sep 2023
US 12,570,727 B2This patent

From the US filing history. Foreign family members aren’t listed.

Timeline

Citations

Open elsewhere

patentgrep

Loading patent…

Abstract

Provided herein are antibodies including antigen-binding fragments thereof that specifically recognizing Pseudomonas Psl. Also provided are methods of making and using these antibodies.

An isolated antibody or antigen binding fragment thereof which specially binds to Pseudomonas Psl, comprises:

a VH comprising an HC-CDR1 comprising the amino acid sequence of SEQ ID NO:
1, an HC-CDR2 comprising the amino acid sequence of SEQ ID NO:
13, and an HC-CDR3 comprising the amino acid sequence of SEQ ID NO:
24;
and a VL comprising an LC-CDR1 comprising the amino acid sequence of SEQ ID NO:
37, an LC-CDR2 comprising the amino acid sequence of SEQ ID NO:
51, and an LC-CDR3 comprising the amino acid sequence of SEQ ID NO:
62;
(ii) a VH comprising an HC-CDR1 comprising the amino acid sequence of SEQ ID NO:
1, an HC-CDR2 comprising the amino acid sequence of SEQ ID NO:
163, and an HC-CDR3 comprising the amino acid sequence of SEQ ID NO:
171;
and a VL comprising an LC-CDR1 comprising the amino acid sequence of SEQ ID NO:
37, an LC-CDR2 comprising the amino acid sequence of SEQ ID NO:
51, and an LC-CDR3 comprising the amino acid sequence of SEQ ID NO:
62;
(iii) a VH comprising an HC-CDR1 comprising the amino acid sequence of SEQ ID NO:
1, an HC-CDR2 comprising the amino acid sequence of SEQ ID NO:
163, and an HC-CDR3 comprising the amino acid sequence of SEQ ID NO:
172;
and a VL comprising an LC-CDR1 comprising the amino acid sequence of SEQ ID NO:
37, an LC-CDR2 comprising the amino acid sequence of SEQ ID NO:
51, and an LC-CDR3 comprising the amino acid sequence of SEQ ID NO:
62;
(iv) a VH comprising an HC-CDR1 comprising the amino acid sequence of SEQ ID NO:
1, an HC-CDR2 comprising the amino acid sequence of SEQ ID NO:
163, and an HC-CDR3 comprising the amino acid sequence of SEQ ID NO:
173;
and a VL comprising an LC-CDR1 comprising the amino acid sequence of SEQ ID NO:
37, an LC-CDR2 comprising the amino acid sequence of SEQ ID NO:
51, and an LC-CDR3 comprising the amino acid sequence of SEQ ID NO:
62;
(v) a VH comprising an HC-CDR1 comprising the amino acid sequence of SEQ ID NO:
1, an HC-CDR2 comprising the amino acid sequence of SEQ ID NO:
163, and an HC-CDR3 comprising the amino acid sequence of SEQ ID NO:
36;
and a VL comprising an LC-CDR1 comprising the amino acid sequence of SEQ ID NO:
37, an LC-CDR2 comprising the amino acid sequence of SEQ ID NO:
51, and an LC-CDR3 comprising the amino acid sequence of SEQ ID NO:
62;
(vi) a VH comprising an HC-CDR1 comprising the amino acid sequence of SEQ ID NO:
1, an HC-CDR2 comprising the amino acid sequence of SEQ ID NO:
163, and an HC-CDR3 comprising the amino acid sequence of SEQ ID NO:
174;
and a VL comprising an LC-CDR1 comprising the amino acid sequence of SEQ ID NO:
37, an LC-CDR2 comprising the amino acid sequence of SEQ ID NO:
51, and an LC-CDR3 comprising the amino acid sequence of SEQ ID NO:
62;
(vii) a VH comprising an HC-CDR1 comprising the amino acid sequence of SEQ ID NO:
1, an HC-CDR2 comprising the amino acid sequence of SEQ ID NO:
163, and an HC-CDR3 comprising the amino acid sequence of SEQ ID NO:
175;
and a VL comprising an LC-CDR1 comprising the amino acid sequence of SEQ ID NO:
37, an LC-CDR2 comprising the amino acid sequence of SEQ ID NO:
51, and an LC-CDR3 comprising the amino acid sequence of SEQ ID NO:
62;
(viii) a VH comprising an HC-CDR1 comprising the amino acid sequence of SEQ ID NO:
1, an HC-CDR2 comprising the amino acid sequence of SEQ ID NO:
163, and an HC-CDR3 comprising the amino acid sequence of SEQ ID NO:
176;
and a VL comprising an LC-CDR1 comprising the amino acid sequence of SEQ ID NO:
37, an LC-CDR2 comprising the amino acid sequence of SEQ ID NO:
51, and an LC-CDR3 comprising the amino acid sequence of SEQ ID NO:
62;
(ix) a VH comprising an HC-CDR1 comprising the amino acid sequence of SEQ ID NO:
1, an HC-CDR2 comprising the amino acid sequence of SEQ ID NO:
163, and an HC-CDR3 comprising the amino acid sequence of SEQ ID NO:
177;
and a VL comprising an LC-CDR1 comprising the amino acid sequence of SEQ ID NO:
37, an LC-CDR2 comprising the amino acid sequence of SEQ ID NO:
51, and an LC-CDR3 comprising the amino acid sequence of SEQ ID NO:
62;
(x) a VH comprising an HC-CDR1 comprising the amino acid sequence of SEQ ID NO:
1, an HC-CDR2 comprising the amino acid sequence of SEQ ID NO:
163, and an HC-CDR3 comprising the amino acid sequence of SEQ ID NO:
178;
and a VL comprising an LC-CDR1 comprising the amino acid sequence of SEQ ID NO:
37, an LC-CDR2 comprising the amino acid sequence of SEQ ID NO:
51, and an LC-CDR3 comprising the amino acid sequence of SEQ ID NO:
62;
(xi) a VH comprising an HC-CDR1 comprising the amino acid sequence of SEQ ID NO:
1, an HC-CDR2 comprising the amino acid sequence of SEQ ID NO:
163, and an HC-CDR3 comprising the amino acid sequence of SEQ ID NO:
179;
and a VL comprising an LC-CDR1 comprising the amino acid sequence of SEQ ID NO:
37, an LC-CDR2 comprising the amino acid sequence of SEQ ID NO:
51, and an LC-CDR3 comprising the amino acid sequence of SEQ ID NO:
62;
(xii) a VH comprising an HC-CDR1 comprising the amino acid sequence of SEQ ID NO:
1, an HC-CDR2 comprising the amino acid sequence of SEQ ID NO:
163, and an HC-CDR3 comprising the amino acid sequence of SEQ ID NO:
180;
and a VL comprising an LC-CDR1 comprising the amino acid sequence of SEQ ID NO:
37, an LC-CDR2 comprising the amino acid sequence of SEQ ID NO:
51, and an LC-CDR3 comprising the amino acid sequence of SEQ ID NO:
62;
(xiii) a VH comprising an HC-CDR1 comprising the amino acid sequence of SEQ ID NO:
1, an HC-CDR2 comprising the amino acid sequence of SEQ ID NO:
13, and an HC-CDR3 comprising the amino acid sequence of SEQ ID NO:
181;
and a VL comprising an LC-CDR1 comprising the amino acid sequence of SEQ ID NO:
37, an LC-CDR2 comprising the amino acid sequence of SEQ ID NO:
51, and an LC-CDR3 comprising the amino acid sequence of SEQ ID NO:
62;
(xiv) a VH comprising an HC-CDR1 comprising the amino acid sequence of SEQ ID NO:
1, an HC-CDR2 comprising the amino acid sequence of SEQ ID NO:
163, and an HC-CDR3 comprising the amino acid sequence of SEQ ID NO:
182;
and a VL comprising an LC-CDR1 comprising the amino acid sequence of SEQ ID NO:
37, an LC-CDR2 comprising the amino acid sequence of SEQ ID NO:
51, and an LC-CDR3 comprising the amino acid sequence of SEQ ID NO:
62;
(xv) a VH comprising an HC-CDR1 comprising the amino acid sequence of SEQ ID NO:
1, an HC-CDR2 comprising the amino acid sequence of SEQ ID NO:
163, and an HC-CDR3 comprising the amino acid sequence of SEQ ID NO:
185;
and a VL comprising an LC-CDR1 comprising the amino acid sequence of SEQ ID NO:
37, an LC-CDR2 comprising the amino acid sequence of SEQ ID NO:
51, and an LC-CDR3 comprising the amino acid sequence of SEQ ID NO:
62;
or
(xvi) a VH comprising an HC-CDR1 comprising the amino acid sequence of SEQ ID NO:
1, an HC-CDR2 comprising the amino acid sequence of SEQ ID NO:
163, and an HC-CDR3 comprising the amino acid sequence of SEQ ID NO:
186;
and a VL comprising an LC-CDR1 comprising the amino acid sequence of SEQ ID NO:
37, an LC-CDR2 comprising the amino acid sequence of SEQ ID NO:
51, and an LC-CDR3 comprising the amino acid sequence of SEQ ID NO:
62.

126 more elements

Facts

Application

18/020,180Filed 4 Aug 2021

Priority

WO PCT/CN2020/1076667 Aug 2020

Published

US 2023/0295279 A121 Sep 2023

Granted

10 Mar 2026

Term ends

Not estimatedThe source records don’t support an estimate.

Classification21 codes

C07K 16/1214
Gram-negative bacteria: pseudomonadaceae
A61K 39/395
Medicinal preparations containing antigens or antibodies: antibodies ; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
A61P 31/04
Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics: antibacterial agents
C12N 15/85
Vectors or expression systems specially adapted for eukaryotic hosts: for animal cells